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ARTICLE OPEN
Recruitment of patients with Chronic Obstructive Pulmonary
Disease (COPD) from the Clinical Practice Research Datalink
(CPRD) for research
Jennifer K. Quint 1, Elisabeth Moore1, Adam Lewis1, Maimoona Hashmi2, Kirin Sultana2, Mark Wright2, Liam Smeeth3,
Lia Chatzidiakou 4, Roderic Jones4, Sean Beevers5, Sefki Kolozali5, Frank Kelly6 and Benjamin Barratt6
Databases of electronic health records (EHR) are not only a valuable source of data for health research but have also recently been
used as a medium through which potential study participants can be screened, located and approached to take part in research.
The aim was to assess whether it is feasible and practical to screen, locate and approach patients to take part in research through
the Clinical Practice Research Datalink (CPRD). This is a cohort study in primary care. The CPRD anonymised EHR database was
searched to screen patients with Chronic Obstructive Pulmonary Disease (COPD) to take part in a research study. The potential
participants were contacted via their General Practitioner (GP) who conﬁrmed their eligibility. Eighty two practices across Greater
London were invited to the study. Twenty-six (31.7%) practices consented to participate resulting in a pre-screened list of 988
patients. Of these, 632 (63.7%) were conﬁrmed as eligible following the GP review. Two hundred twenty seven (36%) response
forms were received by the study team; 79 (34.8%) responded ‘yes’ (i.e., they wanted to be contacted by the research assistant for
more information and to talk about enrolling in the study), and 148 (65.2%) declined participation. This study has shown that it is
possible to use EHR databases such as CPRD to screen, locate and recruit participants for research. This method provides access to a
cohort of patients while minimising input needed by GPs and allows researchers to examine healthcare usage and disease burden
in more detail and in real-life settings.
npj Primary Care Respiratory Medicine  (2018) 28:21 ; doi:10.1038/s41533-018-0089-3
INTRODUCTION
Recruitment for health research traditionally involves approaches
being made to individual healthcare professionals to undertake a
time-consuming, labour intensive search of their own patient
records. In an increasingly demanding clinical setting, this may
limit opportunity for participant uptake.
More recently, studies have adopted other means, such as
utilising electronic health records (EHR) to screen and locate
potentially suitable participants nationally. This method has been
demonstrated to be effective in a genotoxicity study requiring the
collection of a biosample from patients1 and in a cluster
randomised asthma study involving the delivery of a simple
intervention.2
The present study investigated the association between
environmental exposures and exacerbations of Chronic Obstruc-
tive Pulmonary Disease (COPD).3 The Clinical Practice Research
Datalink (CPRD) anonymised General Practitioner (GP) record
database was used to screen and locate eligible study participants,
in a restricted geographical region, who were identiﬁed at the
practice and invited to take part in the study. Participants were
required to carry an environmental monitoring device for
6 months, undertake lung function tests and complete diary
symptoms cards; response rates and lessons learned from using
this method are examined in this report.
RESULTS
Figure 1 shows the ﬂow of potentially eligible patients and their
practices through the study. The study stage is indicated by the
column on the left and corresponding practice and patient
numbers are shown. Eighty-two practices were invited to the
study of which 56 (68.3%) did not take part, of these 17.9%
indicated they had ‘too much workload at present’ to complete
the study activities and a small number expressed reasons of
‘insufﬁcient resources’ or ‘not enough remuneration’, this effec-
tively resulted in a loss of 2073 (67.7%) patients who might
otherwise have been considered in the study. Twenty-six (31.7%)
practices consented to participate resulting in a pre-screened list
of 988 patients. Of these, 632 (63.9%) were considered eligible
following GP review and 359/988 (36.3%) excluded; 104 (10.5%)
no longer ﬁtted the study criteria (e.g., no diagnosis of COPD, no
exacerbations in the last year, or patient was a current smoker),
and a further of 255 (23%) deemed unsuitable to participate by
the GP; 220 (22.3%) were either housebound, suffering from
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dementia or other co-morbidities, and 35 (3.5%) had transferred
from the practice and were no longer contactable for the study.
The patient recruitment period ran from December 2015 to
February 2017. GP practices were invited to take part with some
practices being approached several times.
Figure 2 shows the number of GP practices invited to
participate during the recruitment phase and the number of
participating practices. Recruitment was slower during the winter
period. Searches were adapted (e.g., a wider area searched) during
the course of the recruitment period.
A total of 632 patients were approached and returned 227
(36%) response forms: 148 (65.2%) declined participation, 79
(34.8%) responded ‘yes’ (i.e., they wanted to be contacted by the
research assistant for more information and to talk about enrolling
in the study) and 66 (29%) were enrolled. Figure 3 shows the main
reasons for patients declining were ‘study too demanding’ (34%),
and ‘not interested in the study’ (17%).
DISCUSSION
Summary
This study has demonstrated how an EHR database can be used to
screen suitable participants and locate their registered practice,
minimising input needed by busy GPs and health care profes-
sionals in secondary care. This strategy reduces the recruitment
burden and increases the recruitment pool. In addition, patients
may be offered the chance to take part in research who otherwise
may not be presented with this opportunity as they are not known
to secondary care or do not frequently visit their GP.
Strengths and limitations
One of the advantages of this method is that researchers can link
EHR, with data on medications and GP visits, to hospital visits
(Hospital Episode Statistics) and mortality records (Ofﬁce of
National Statistics) to examine healthcare usage and disease
burden in more detail. This reduces information that needs to be
self-reported by study participants thus shortening their study
visits, and improving accuracy of data collected (sometimes exact
timing of events cannot be recalled by patients, in particular exact
timing of acute events4). Furthermore, the health data can be
linked to other data, for example in the case of the COPE study to
diverse exposure estimations (e.g., data from air quality monitors/
mobility data).
This method relied on GPs reviewing a pre-screened patient list
and sending out study information packs. Although GPs were
reimbursed for taking part, some GP practices declined
Fig. 1 COPE study patient eligibility ﬂow
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participation because of busy workloads, or did not respond
resulting in almost two thirds of patients excluded from being
screened for this study (Fig. 1). This approach is limited to GP
practices registered with electronic healthcare systems such as
CPRD but many are not and therefore there are patients who are
not accessible through this method. 31.7% of eligible practices
distributed across London agreed to participate in this study.
Whilst CPRD invited practices in the greater London area to take
part, there is no discernible difference between practices who
agreed to take part or did not agree to suggest this would result in
patient selection bias. The only difference between those practices
that took part and those that didn’t was due to available workload
at the time of being approached.
We used validated deﬁnitions with a high positive predictive
value (PPV) to identify those with COPD and so it is unlikely that
eligible patients will have been missed, however, we recognise
that there are likely to be some coding differences between GPs
but were not able to evaluate this misclassiﬁcation. Despite using
the validated codelists and algorithm, some patients no longer
ﬁtted the study criteria perhaps because their diagnosis had
changed over time. Within EHRs one diagnosis may not supersede
a previously recorded diagnosis which was included in the
screening criteria. The majority of these were identiﬁed by the GP
and a much smaller number subsequently by the research team.
This is unlikely to be a COPD speciﬁc phenomenon and needs to
be considered when using this method for any disease. This also
highlights the importance of periodically reviewing the search
criteria or presenting up to date pre-screened patient lists for GP
review to reduce the possibilities of inviting patients who no
longer meet the eligibility criteria. GP screening was also useful in
indicating those patients that were unable/unsuitable to take part
for reasons such as being housebound or who had co-morbidities
that may limit participation. Often this was for social reasons or
frailty, which would not have been readily detected from the
study search algorithms alone or were not included in the search
engine and suggests further improvements can be made to the
search criteria. The ﬁnal number of patients enrolled from CPRD
into the study was 66 (41%) of the 160 patient recruitment target
(6.6% patients enrolled from 988 screened patients); 227/629
(36%) patients contacted the research site of which 29% (66) were
enrolled. A higher percentage of patients took part in the study
than GPs despite the demands of the study on the patient.
Primary care recruitment numbers to trials using CPRD are likely
to be higher than from practices who do not use CPRD as is shown
in comparison to Davey et al.5 who achieved a recruitment rate of
2.3% by using similar methods without the collaboration of CPRD
or a double screening process. In the COPE study, all GP practices
and participants understood issues of access to patient records
and conﬁdentiality within CPRD contract agreements and Patient
Study Information Sheets. The codelists and algorithms used have
Fig. 2 COPE site recruitment
Fig. 3 Reasons for declining to participate
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previously been validated and all GP practices and participants
understood issues of access to patient records and conﬁdentiality
within CPRD contract agreements and Patient study Information
Sheets. To explain in more detail; CPRD has a pseudo-anonymised
database and only the GP can identify the patient. CPRD operates
an opt-in model whereby a GP practice must provide consent for
CPRD to collect de-identiﬁed primary care data from their practice.
This consent must ﬁrst be in place to enable extractions of data
from the primary care EHR. Patients at participating practices have
the right to opt-out of sharing and use of their data for research at
any time and CPRD respects this choice. Patients are informed that
their data are used for public health research and how they can
opt-out, via a Fair Processing Notice displayed in the practice
waiting room. The CPRD website also provides detailed informa-
tion for the public informing them of the uses of their data for
research purposes and the legal and ethical permissions obtained.
GP practices who agreed to participate in this research did so with
the knowledge that patient anonymity would be protected. No
informed consent is necessary in order to receive information
packs.
Comparison with existing literature
Whilst data from EHRs have been used in thousands of peer
reviewed papers, there has been less use of EHR for patient
recruitment in studies. Those studies that have utilised EHR to
screen for potentially suitable participants for recruitment have
been in different disease areas including cardiovascular,1 asthma,2
and osteoarthritis.5 From the latter study there is an inference that
this approach may not be optimal and other methods such as
newspaper recruitment may be cheaper and easier. Recruitment
in primary care is used in the COPE study to provision a study in
secondary care. Importantly the ﬁndings of the COPE study
demonstrates that EHR recruitment in primary care is a feasible
approach that can be optimised.
We feel that this recruitment strategy may not be directly
compared to strategies used by the pharmaceutical industry,
although we acknowledge that a few pharmaceutical companies
may use PIC as a strategy for recruitment of patients. There are
signiﬁcant differences in the amounts of funding available in
research with Pharmaceutical company involvement. For example,
the £80 million pound investment by GSK in the Salford Lung
Study14. Signiﬁcant pharmaceutical trials do not state their
recruitment strategy within their methodology.6–9 Only one of
these trials stated how many patients were screened8 and it is
likely with the numbers of centres participating (356 centres in 43
countries) that screening was performed directly within secondary
care, and therefore a highly speciﬁc group of patients. Further-
more, the concept and delivery of drug trials compared to our
study are signiﬁcantly different.
Patients received a personalised feedback report but were not
offered any change or potential improvement to their direct
medical care as part of our study and this may be a reason for a
lower why recruitment rate than might be seen for a drug
treatment study. Indeed a systematic review of recruitment
strategies suggests that recruitment into trials is higher when
patients are offered free medication.10 Ngune et al.10 also
recommend providing ﬁnancial incentives. In this study, partici-
pants were offered £20 for participation and GP practices were
paid up to £100 for reviewing patient screening lists and £25 per
patient enrolled to be involved in this study.
Implications for research and clinical practice
This paper presents the ﬁndings of a novel recruitment approach
for a study in secondary care based in primary care, and that may
inform care of COPD patients in primary care. Thus providing
access to a cohort of patients whilst minimising input needed by
GPs and by researchers in secondary care. Furthermore, this study
demonstrates that patients can be conveniently located in a
geographical location for a secondary care site, reducing the
research burden for patients. This recruitment methodology is not
previously published in the BMJ Open protocol paper.3 This
strategy is applicable to other regions in the UK, and to other
specialities besides respiratory care. A further advantage of this
method is that researchers can link data from a variety of sources
such as electronic healthcare records, secondary data repository
such as Hospital Episode Statistics (HES) together with data
obtained directly from the patient (such as patient diaries and
additional tests). An adequate number of patients can be enrolled
by this method, as evidenced in this study, but thought needs to
be given to increasing patient participation, for example looking
at strategies to reduce research burden.
METHODS
CPRD holds an anonymised GP records database containing continually
updated primary care medical data. This database includes details on
symptoms, diagnoses, tests, prescriptions, patient demographics, health
behaviours, and referrals to secondary care. Details in CPRD are mainly
recorded using a system of Read codes, which is a polyhierarchical
terminology system. The CPRD database is broadly representative of the
UK general population.11
Validated codelists and algorithms12,13 created by members of the study
team were used by CPRD researchers to screen patients based on the
following eligibility criteria; diagnosis of moderate or severe COPD, with at
least one COPD exacerbation in the year preceding study start, age 35 and
above with evidence of smoking history. Current smokers were excluded
from the search criteria. The CPRD EHR database was interrogated by CPRD
researchers using a search engine enabled by the deﬁned codelists and
algorithms to create a pre-screened list of patients that met the protocol
inclusion and exclusion criteria and were registered within practices close
to the research sites in central London.
GP practices that had agreed to participate in research through CPRD
were provided with a pre-screened list from which to identify and select
suitable patients to receive information about the study. GPs gave
conﬁrmation to CPRD of patients who they thought were suitable for the
study and received participant information packs from CPRD to send to
potential recruits. The information pack contained a cover letter from the
GP introducing the study, a patient information leaﬂet, and a response
form that participants could complete and send to the research team in a
pre-paid envelope to be contacted or to decline to take part. The research
coordinator was then able to contact the participants, discuss the study,
and invite them to enrol through a clinic appointment. Participants were
required to carry a personal air monitor for 1 day a week for 6 months,
undertake three lung function tests, record on a dairy card any
exacerbations, sleep disturbance, changes to their regular treatment and
to record their peak ﬂow reading each morning.3 Output from the
monitors were then linked with the EHR data to obtain information on
COPD management, severity, co-morbidities and exacerbations. Linked
data (Hospital Episode Statistics, Ofﬁce of National Statistics, and Index of
Multiple Deprivation/Townsend Score) was collected for enrolled patients.
This study aimed to recruit 160 COPD patients. The study was reviewed by
the Independent Scientiﬁc Advisory Committee (ref 15052) and approval
conﬁrmed by Camden and Islington Research Ethics Committee (ref 14/LO/
2216). The CPRD database has been used for many epidemiological studies
where patient data is accessed and used in publication. Annual research
ethics approval from a NHS Health Research Authority (HRA) Research
Ethics Committee (REC) is required to permit the collection and supply of
anonymised patient data for Observational Research.
Data availability
All data generated and analysed during the current study are available
from the corresponding author on reasonable request.
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